These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

689 related items for PubMed ID: 20022918

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Stability engineering of scFvs for the development of bispecific and multivalent antibodies.
    Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS, Glaser SM.
    Protein Eng Des Sel; 2010 Jul; 23(7):549-57. PubMed ID: 20457695
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.
    Vendel MC, Favis M, Snyder WB, Huang F, Capili AD, Dong J, Glaser SM, Miller BR, Demarest SJ.
    Arch Biochem Biophys; 2012 Oct 15; 526(2):188-93. PubMed ID: 22230329
    [Abstract] [Full Text] [Related]

  • 8. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X, Sereno AJ, Huang F, Lewis SM, Lieu RL, Weldon C, Torres C, Fine C, Batt MA, Fitchett JR, Glasebrook AL, Kuhlman B, Demarest SJ.
    MAbs; 2015 Oct 15; 7(3):470-82. PubMed ID: 25774965
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK.
    Q J Nucl Med; 1998 Dec 15; 42(4):225-41. PubMed ID: 9973838
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Identification of potent human anti-IL-1RI antagonist antibodies.
    Fredericks ZL, Forte C, Capuano IV, Zhou H, Vanden Bos T, Carter P.
    Protein Eng Des Sel; 2004 Jan 15; 17(1):95-106. PubMed ID: 14985542
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, Rickert M, Appah CT, Pascua E, Radcliffe T, Sutton J, Chaparro-Riggers J, Chen W, Casas MG, Chin SM, Wong OK, Liu SH, Vergara G, Shelton D, Rajpal A, Pons J.
    J Mol Biol; 2012 Jul 13; 420(3):204-19. PubMed ID: 22543237
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
    Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, Huang F, Phan S, Gao S, Doern A, Farrington GK, Lugovskoy A, Joseph I, Bailly V, Wang X, Garber E, Browning J, Glaser SM.
    MAbs; 2009 Jul 13; 1(2):128-41. PubMed ID: 20061822
    [Abstract] [Full Text] [Related]

  • 16. Nanocell targeting using engineered bispecific antibodies.
    Taylor K, Howard CB, Jones ML, Sedliarou I, MacDiarmid J, Brahmbhatt H, Munro TP, Mahler SM.
    MAbs; 2015 Jul 13; 7(1):53-65. PubMed ID: 25523746
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Neutralizing murine monoclonal antibodies to human IL-5 isolated from hybridomas and a filamentous phage Fab display library.
    Ames RS, Tornetta MA, McMillan LJ, Kaiser KF, Holmes SD, Appelbaum E, Cusimano DM, Theisen TW, Gross MS, Jones CS.
    J Immunol; 1995 Jun 15; 154(12):6355-64. PubMed ID: 7759873
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.